Literature DB >> 22386178

Clinical findings and diagnosis in human granulocytic anaplasmosis: a case series from Massachusetts.

Ana A Weil1, Elinor L Baron, Catherine M Brown, Mark S Drapkin.   

Abstract

OBJECTIVE: To describe clinical findings and the use of a tick-associated pathogen panel in a series of patients with human granulocytic anaplasmosis (HGA) at a suburban Boston hospital. PATIENTS AND METHODS: Medical records were reviewed for inpatients and outpatients at Newton-Wellesley Hospital with a positive polymerase chain reaction (PCR) result for Anaplasma phagocytophilum during the study period March 1 through November 30, 2009. A PCR panel was used to test for tick-borne pathogens. Postal ZIP code data from the patients' areas of residence were used to estimate the area of disease transmission.
RESULTS: Thirty-three cases were confirmed during the 2009 transmission season, and 14 of these patients (42%) required hospitalization. Thrombocytopenia and/or leukopenia were observed at the time of presentation in 25 of 30 patients (86%) in whom both white blood cell and platelet counts were determined, and 28 of 33 patients (85%) reported fever. Rash occurred in only 2 of the 33 patients (6%), and 25 (76%) reported one or more respiratory or gastrointestinal symptom. Cases were geographically distributed diffusely throughout the hospital catchment area, with one possible focus of infection identified in Weston, MA. Due to a lack of clinical data reporting to the Massachusetts Department of Public Health, only 20 of 32 HGA cases (63%) fulfilled the case confirmation criteria.
CONCLUSION: Diagnosis of HGA requires a high suspicion for infection even in endemic areas. Use of a tick-associated pathogen panel that includes PCR assays for several organisms could improve detection of underrecognized tick-borne diseases in endemic areas. Lack of epidemiological follow-up to confirm corroborating clinical findings prevents accurate case reporting and assessment of the true HGA burden.
Copyright © 2012 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22386178      PMCID: PMC3498394          DOI: 10.1016/j.mayocp.2011.09.008

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  20 in total

1.  Lyme disease and preventive behaviors in residents of Nantucket Island, Massachusetts.

Authors:  C B Phillips; M H Liang; O Sangha; E A Wright; A H Fossel; R A Lew; K K Fossel; N A Shadick
Journal:  Am J Prev Med       Date:  2001-04       Impact factor: 5.043

2.  Seroprevalence and seroconversion for tick-borne diseases in a high-risk population in the northeast United States.

Authors:  E Hilton; J DeVoti; J L Benach; M L Halluska; D J White; H Paxton; J S Dumler
Journal:  Am J Med       Date:  1999-04       Impact factor: 4.965

3.  Seroprevalence of human granulocytic ehrlichiosis among permanent residents of northwestern Wisconsin.

Authors:  J S Bakken; P Goellner; M Van Etten; D Z Boyle; O L Swonger; S Mattson; J Krueth; R L Tilden; K Asanovich; J Walls; J S Dumler
Journal:  Clin Infect Dis       Date:  1998-12       Impact factor: 9.079

4.  Human granulocytic ehrlichiosis: a case series from a medical center in New York State.

Authors:  M E Aguero-Rosenfeld; H W Horowitz; G P Wormser; D F McKenna; J Nowakowski; J Muñoz; J S Dumler
Journal:  Ann Intern Med       Date:  1996-12-01       Impact factor: 25.391

5.  Human granulocytic ehrlichiosis in Massachusetts.

Authors:  S R Telford; T J Lepore; P Snow; C K Warner; J E Dawson
Journal:  Ann Intern Med       Date:  1995-08-15       Impact factor: 25.391

6.  PCR amplification and comparison of nucleotide sequences from the groESL heat shock operon of Ehrlichia species.

Authors:  J W Sumner; W L Nicholson; R F Massung
Journal:  J Clin Microbiol       Date:  1997-08       Impact factor: 5.948

7.  Detection of Borrelia burgdorferi, Ehrlichia chaffeensis, and Anaplasma phagocytophilum in ticks (Acari: Ixodidae) from a coastal region of California.

Authors:  Kevin Holden; John T Boothby; Sulekha Anand; Robert F Massung
Journal:  J Med Entomol       Date:  2003-07       Impact factor: 2.278

8.  Epidemiology of human ehrlichiosis and anaplasmosis in the United States, 2001-2002.

Authors:  Linda J Demma; Robert C Holman; Jennifer H McQuiston; John W Krebs; David L Swerdlow
Journal:  Am J Trop Med Hyg       Date:  2005-08       Impact factor: 2.345

Review 9.  The human ehrlichioses in the United States.

Authors:  J H McQuiston; C D Paddock; R C Holman; J E Childs
Journal:  Emerg Infect Dis       Date:  1999 Sep-Oct       Impact factor: 6.883

Review 10.  Molecular diagnosis of human granulocytic anaplasmosis.

Authors:  J Stephen Dumler; Philippe Brouqui
Journal:  Expert Rev Mol Diagn       Date:  2004-07       Impact factor: 5.225

View more
  11 in total

Review 1.  The role of CD8 T lymphocytes in rickettsial infections.

Authors:  David H Walker; J Stephen Dumler
Journal:  Semin Immunopathol       Date:  2015-04-01       Impact factor: 9.623

2.  Use of Routine Complete Blood Count Results to Rule Out Anaplasmosis Without the Need for Specific Diagnostic Testing.

Authors:  Sarah E Turbett; Melis N Anahtar; Vikram Pattanayak; Marwan M Azar; K C Coffey; George Eng; Joseph W Rudolf; Kent B Lewandrowski; Jason Baron; Eric S Rosenberg; John A Branda
Journal:  Clin Infect Dis       Date:  2020-03-03       Impact factor: 9.079

Review 3.  Diagnosis, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: A Review.

Authors:  Edgar Sanchez; Edouard Vannier; Gary P Wormser; Linden T Hu
Journal:  JAMA       Date:  2016-04-26       Impact factor: 56.272

4.  Differences and similarities between culture-confirmed human granulocytic anaplasmosis and early lyme disease.

Authors:  Gary P Wormser; Maria E Aguero-Rosenfeld; Mary E Cox; John Nowakowski; Robert B Nadelman; Diane Holmgren; Donna McKenna; Susan Bittker; Lois Zentmaier; Denise Cooper; Dionysios Liveris; Ira Schwartz; Harold W Horowitz
Journal:  J Clin Microbiol       Date:  2013-01-09       Impact factor: 5.948

5.  Severe Human Granulocytic Anaplasmosis With Significantly Elevated Ferritin Levels in an Immunocompetent Host in Pennsylvania: A Case Report.

Authors:  Mona L Camacci; Ronaldo Paolo Panganiban; Zachary Pattison; Kamyar Haghayeghi; Alexander Daly; Cindy Ojevwe; Ryan J Munyon
Journal:  J Investig Med High Impact Case Rep       Date:  2018-02-13

6.  Anaplasmosis: An emerging tick-borne disease of importance in Canada.

Authors:  Kelsey Uminski; Kamran Kadkhoda; Brett L Houston; Alison Lopez; Lauren J MacKenzie; Robbin Lindsay; Andrew Walkty; John Embil; Ryan Zarychanski
Journal:  IDCases       Date:  2018-11-28

7.  Value of PCR, Serology, and Blood Smears for Human Granulocytic Anaplasmosis Diagnosis, France.

Authors:  Yves Hansmann; Benoit Jaulhac; Pierre Kieffer; Martin Martinot; Elisabeth Wurtz; Régis Dukic; Geneviève Boess; André Michel; Christophe Strady; Jean François Sagez; Nicolas Lefebvre; Emilie Talagrand-Reboul; Xavier Argemi; Sylvie De Martino
Journal:  Emerg Infect Dis       Date:  2019-05       Impact factor: 6.883

8.  Clinical Decision Support Trees Can Help Optimize Utilization of Anaplasma phagocytophilum Nucleic Acid Amplification Testing.

Authors:  Robert Hamilton; Torrie R Pandora; Jeffrey Parsonnet; Isabella W Martin
Journal:  J Clin Microbiol       Date:  2021-08-18       Impact factor: 5.948

9.  Structure of the type IV secretion system in different strains of Anaplasma phagocytophilum.

Authors:  Basima Al-Khedery; Anna M Lundgren; Snorre Stuen; Erik G Granquist; Ulrike G Munderloh; Curtis M Nelson; A Rick Alleman; Suman M Mahan; Anthony F Barbet
Journal:  BMC Genomics       Date:  2012-11-29       Impact factor: 3.969

10.  Fever and Cardiac Arrest in a Patient With a Left Ventricular Assist Device.

Authors:  Eugene M Tan; Jasmine R Marcelin; Aaron J Tande; Stacey A Rizza; Nathan W Cummins
Journal:  Open Forum Infect Dis       Date:  2015-03-05       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.